A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis

2018307 citationsJournal Articlebronze Open Access

Authors

Treatment with romosozumab for 12 months increased the spine and hip BMD compared with placebo and was well tolerated in men with osteoporosis.

Good health and well-being

Published in: The Journal of Clinical Endocrinology & Metabolism

Volume 103, Issue 9, pp. 3183-3193

Field-Weighted Citation Impact: 23.60